Tendon & Ligament Repair

Rodent studies show BPC-157 significantly accelerates Achilles tendon healing with improved tensile strength and collagen organisation. (Krivic et al., 2006; Staresinic et al., 2003)

Muscle Healing

Research in the Journal of Orthopaedic Research found BPC-157 accelerated healing of muscle crush injuries, reducing inflammatory markers and restoring function faster than controls.

Gut Protection

Consistent cytoprotective effects on the GI tract — protecting against NSAID-induced damage, ulceration and inflammatory bowel conditions in animal models.

Wound Healing

TB-500 consistently accelerates wound closure in preclinical models with improved re-epithelialisation, increased collagen deposition and reduced scarring.

Cardiac Research

Nature published research showing Thymosin Beta-4 activates dormant epicardial progenitor cells following cardiac injury — significant for cardiac regeneration research.

Musculoskeletal

Animal studies demonstrate reduced recovery time from muscle strains with improved functional recovery and reduced fibrosis.

Collagen Synthesis

Journal of Biomaterials Science studies demonstrate GHK-Cu increases collagen synthesis by up to 70% in fibroblast cultures with significant improvements in skin density.

Wound Healing

Clinical research shows GHK-Cu accelerates wound contraction, re-epithelialisation and scar remodelling.

Hair Follicle

Double-blind trials demonstrate GHK-Cu increases hair follicle size and stimulates growth comparable to established treatments.

Insulin Sensitivity

Lee et al. Cell Metabolism 2015 demonstrated MOTS-c significantly improves insulin sensitivity and glucose homeostasis in diet-induced obese mouse models.

Exercise Mimetic

Nature Communications research shows MOTS-c rises during exercise and exogenous administration mimics metabolic benefits of physical activity in sedentary models.

Longevity

Studies in aged mice demonstrate MOTS-c improves physical performance, metabolic health and extends healthy lifespan.

Phase 2 NEJM Trial (2023)

Demonstrated mean weight reduction of 17.5% at 24 weeks and up to 24.2% at 48 weeks — exceeding all previously published GLP-1 agonist data.

Metabolic Markers

Participants showed significant improvements in blood pressure, lipid profiles, fasting glucose and HbA1c beyond weight reduction alone.

vs Existing Agents

Research models demonstrate superior weight reduction versus dual agonists (tirzepatide) and single agonists (semaglutide).

FDA Approval

Received FDA approval 2010 for reduction of excess abdominal fat in HIV lipodystrophy — Phase 3 trials showing significant visceral fat reduction versus placebo.

Body Composition

Clinical trials demonstrate ~15-20% reduction in visceral adipose tissue over 26 weeks with improvements in waist circumference and lipid profiles.

Cognitive Function

McGill University research demonstrated Tesamorelin improved cognitive function in older adults with mild cognitive impairment — improvements in executive function and verbal memory.

SURMOUNT-1 Trial NEJM 2022

Mean weight reduction of 22.5% over 72 weeks in adults with obesity — the largest weight reduction recorded in a Phase 3 trial at that time.

SURPASS Programme

5 Phase 3 studies demonstrating superior HbA1c reduction and weight loss versus semaglutide, insulin degludec and insulin glargine.

NAFLD/NASH

Research indicates significant reduction in hepatic steatosis and fibrosis markers, expanding applications beyond metabolic disease.

Reconstitution Standard

Universally accepted reconstitution solvent for lyophilised peptides in research settings, compatible with the full Cambrian catalogue.

Stability

Maintains reconstituted peptide stability for up to 28 days at 2-8°C versus 24 hours for sterile water without preservative.

Benzyl Alcohol

At 0.9% concentration provides effective bacteriostatic preservation without significant impact on peptide structure across the research literature.

Energy Metabolism & Mitochondrial Function

NAD+ is an essential cofactor in the mitochondrial electron transport chain. Research published in American Journal of Physiology (2024) confirms NAD+ supplementation supports oxidative phosphorylation and ATP production, with particular relevance in conditions of mitochondrial dysfunction. SIRT1 and SIRT3 activation promotes mitochondrial biogenesis and reduces oxidative stress.

Longevity & Ageing Research

NAD+ levels decline by approximately 50% between the ages of 40 and 60. Preclinical findings consistently link restored NAD+ abundance to improvements in physiological function and healthspan markers. Sirtuins — the longevity-associated protein family — require NAD+ as a cofactor, establishing a direct mechanistic link between NAD+ status and ageing biology. (PMC, 2023)

Cardiovascular Research

A 2023 randomised double-blind placebo-controlled trial (Scientific Reports) found NMN supplementation — which raises NAD+ levels — significantly elevated NAD+ metabolites in serum and showed a trend toward reduced arterial stiffness. Separate cardiovascular research demonstrates NAD+ regulates mitochondrial dynamics and reduces oxidative stress in cardiomyocytes. (PMC, 2024)

Cognitive & Neurological Research

Systematic review published in BMC Neuroscience (2025) found NAD+ precursors consistently improve cognitive function in preclinical models of neurodegeneration, diabetes-associated cognitive decline and ageing. Mechanisms include improved mitochondrial function, reduced neuroinflammation and SIRT3-mediated neuroprotection.